The pill debossed with the imprint IG 283 (frequently misread as “1G 283”) is a generic formulation of Cyclobenzaprine Hydrochloride (10 mg). Originally manufactured by InvaGen Pharmaceuticals (a subsidiary of Cipla), this medication is a widely prescribed skeletal muscle relaxant. It is indicated as an adjunct to rest and physical therapy for the relief of muscle spasms associated with acute, painful musculoskeletal conditions.
Pill Identification
An authentic 10 mg Cyclobenzaprine Hydrochloride tablet with this specific imprint can be identified by the following physical properties:
- Imprint: “IG” on the top line, and “283” directly underneath it on one side. The reverse side is completely plain.
- Color: Yellow.
- Shape: Round.
- Coating: Film-coated for ease of swallowing and to mask the bitter taste of the active ingredient.
- Strength: Contains 10 mg of Cyclobenzaprine Hydrochloride.
Mechanism of Action
Unlike some neuromuscular blockers, cyclobenzaprine does not act directly on skeletal muscle fibers or the motor endplate. Instead, it targets the central nervous system (CNS) to reduce muscle hyperactivity.
Chemically, cyclobenzaprine is structurally related to tricyclic antidepressants (TCAs). It acts primarily within the brain stem rather than the spinal cord. Its mechanism involves:
- Reducing Tonic Somatic Motor Activity: It influences both gamma and alpha motor systems in the brain stem, lowering the baseline firing rate of neurons that cause muscles to tense up.
- Monoaminergic Modulation: It acts as an antagonist at (serotonin) receptors and alters noradrenergic pathways, suppressing hyperactive muscle reflexes without fully disrupting voluntary muscle control or strength.
The therapeutic result is a significant decrease in localized muscle spasms, which subsequently alleviates acute pain and restores range of motion.
Indications & Dosage
Cyclobenzaprine is designed exclusively for short-term use, typically limited to 2 to 3 weeks. Musculoskeletal spasms are generally acute, and long-term efficacy has not been clinically established.
Approved Uses
- Relief of muscle spasms triggered by acute injuries, severe strains, sprains, or lower back trauma.
- Off-Label Use: Sometimes utilized under close physician supervision to manage widespread pain and sleep disturbances associated with fibromyalgia.
Standard Dosage Framework
Dosages must be strictly managed by a healthcare provider to minimize daytime drowsiness.
Patient Population Standard Dosing Protocol Maximum Daily Limit
- Adults & Adolescents (Ages 15+) 5 mg to 10 mg, taken 3 times a day. 30 mg per day (three 10 mg tablets).
- Elderly Patients (Ages 65+) Initiated at a lower dose (e.g., 5 mg) or avoided entirely. Highly restricted due to decreased hepatic clearance.
- Dosing Flexibility: Some patients find success taking a 5 mg or 10 mg dose only at bedtime if the medication causes excessive daytime drowsiness.
Side Effects
Because cyclobenzaprine acts on central neurotransmitters, its side effect profile heavily mirrors its sedative properties.
Common Side Effects
These are usually mild to moderate and frequently taper off as the body adapts to the medication:
- Profound drowsiness, lethargy, and fatigue
- Dry mouth, throat, or nose (due to anticholinergic effects)
- Dizziness or lightheadedness
- Headaches
- Gastrointestinal upset, nausea, or constipation
Serious Side Effects
Discontinue use immediately and contact a healthcare professional if you experience:
- Cardiac Symptoms: Fast, pounding, or irregular heartbeats (tachycardia or arrhythmias), chest pain, or sudden shortness of breath.
- Neurological Disturbances: Confusion, severe disorientation, vivid hallucinations, or extreme clumsiness.
- Urinary Retention: A sudden inability to urinate or difficulty emptying the bladder.
Warnings & Precautions
Due to its structural similarity to tricyclic antidepressants, cyclobenzaprine carries significant safety restrictions regarding certain medical conditions and drug combinations.
Contraindications
Do not take the IG 283 pill if you have any of the following health profiles:
- Recent Heart Attack: Amlodipine/cyclobenzaprine risks are high during the acute recovery phase following a myocardial infarction.
- Cardiac Arrhythmias or Heart Failure: Can exacerbate underlying heart blocks or conduction disturbances.
- Hyperthyroidism: Increases the risk of dangerous heart rhythms.
Critical Drug Interactions
- MAO Inhibitors (MAOIs): Do not take cyclobenzaprine within 14 days of using an MAO inhibitor (such as phenelzine, selegiline, or linezolid). Doing so can trigger a fatal hypertensive crisis or hyperpyretic crisis (dangerously high body temperature).
- Serotonin Syndrome: Co-administration with other serotonergic medications (like SSRIs, SNRIs, or tramadol) can lead to Serotonin Syndrome a potentially life-threatening condition marked by agitation, tremors, muscle rigidity, high fever, and rapid heart rate.
- CNS Depressants: Mixing this pill with alcohol, opioids, sleeping aids, or anti-anxiety medications will dangerously compound central nervous system depression, severely impairing motor coordination and respiratory function.
General Precautions
- Impaired Alertness: Avoid driving, operating machinery, or performing dangerous tasks until you are completely certain how a 10 mg dose affects your level of alertness.
- Hepatic Impairment: Patients with mild-to-moderate liver disease require significant dose reductions, as the drug can accumulate rapidly in hepatic tissue.